Systems-level G protein-coupled receptor therapy across a neurodegenerative continuum by the GLP-1 receptor system

Frontiers in Endocrinology

Volumn 5, Issue SEP, 2014, Pages

  Janssens, Jonathan ^a   Etienne, Harmonie ^a   Idriss, Sherif ^a   Azmi, Abdelkrim ^a   Martin, Bronwen ^b   Maudsley, Stuart ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Heptahelical G protein coupled receptor; Pathophysiology; Pharmacotherapeutics; Transcriptomics and proteomics

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PRESENILIN 1; PRESENILIN 2;

ADIPOSE TISSUE; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CELL INFILTRATION; CIRCADIAN RHYTHM; DEGENERATIVE DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; GASTROINTESTINAL TRACT FUNCTION; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; LIPID METABOLISM; METABOLIC SYNDROME X; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SENSORY DYSFUNCTION; SLEEP DISORDER;

EID: 84987781385     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00142     Document Type: Review

References (209)

1. Maudsley S, Martin B, Luttrell LM. The origins of diversity and specificity in G protein-coupled receptor signaling. J Pharmacol Exp Ther (2005) 314(2):485-94. doi: 10.1124/jpet.105.083121
2. Brink CB, Harvey BH, Bodenstein J, Venter DP, Oliver DW. Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology. Br J Clin Pharmacol (2004) 57(4):373-87. doi:10.1111/j.1365-2125.2003.02046.x
3. Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett (2002) 520:97-101. doi:10.1016/S0014-5793(02)02775-8
4. Chadwick W, Maudsley S. The devil is in the dose: complexity of receptor systems and responses. In: Mattson MP, Calabrese EJ, editors. Hormesis: A Revolution in Biology, Toxicology and Medicine. Springer-Verlag (2010). p. 95-108.
5. Fredriksson R, Schiöth HB. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol (2005) 67(5):1414-25. doi:10.1124/mol.104.009001
6. Maudsley S, Martin B, Luttrell LM. G protein-coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics. Curr Alzheimer Res (2007) 4(1):3-19. doi:10.2174/156720507779939850
7. Maurice P, Guillaume JL, Benleulmi-Chaachoua A, Daulat AM, Kamal M, Jockers R. GPCR-interacting proteins, major players of GPCR function. Adv Pharmacol (2011) 62:349-80. doi:10.1016/B978-0-12-385952-5.00001-4
8. Maudsley S, Siddiqui S, Martin B. Systems analysis of arrestin pathway functions. Prog Mol Biol Transl Sci (2013) 118:431-67. doi:10.1016/B978-0-12-394440-5.00017-6
9. Gesty-Palmer D, Yuan L, Martin B, Wood WH III, Lee MH, Janech MG, et al. ß-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Mol Endocrinol (2013) 27(2):296-314. doi:10.1210/me.2012-1091
10. Maudsley S, Patel SA, Park SS, Luttrell LM, Martin B. Functional signaling biases in G protein-coupled receptors: game theory and receptor dynamics. Mini Rev Med Chem (2012) 12(9):831-40. doi:10.2174/138955712800959071
11. Gesty-Palmer D, Luttrell LM. Refining efficacy: exploiting functional selectivity for drug discovery. Adv Pharmacol (2011) 62:79-107. doi:10.1016/B978-0-12-385952-5.00009-9
12. Maudsley S, Davidson L, Pawson AJ, Chan R, López de Maturana R, Millar RP. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res (2004) 64(20):7533-44. doi:10.1158/0008-5472.CAN-04-1360
13. Gesty-Palmer D, Luttrell LM. Heptahelical terpsichory. Who calls the tune? J Recept Signal Transduct Res (2008) 28(1-2):39-58. doi:10.1080/10799890801941921
14. Wang L, Chadwick W, Park SS, Zhou Y, Silver N, Martin B, et al. Gonadotropin-releasing hormone receptor system: modulatory role in aging and neurodegeneration. CNS Neurol Disord Drug Targets (2010) 9(5):651-60. doi:10.2174/187152710793361559
15. Tiwary BK. Correlated evolution of gonadotropin-releasing hormone and gonadotropin-inhibitory hormone and their receptors in mammals. Neuroendocrinology (2013) 97(3):242-51. doi:10.1159/000342694
16. Kim DK, Cho EB, Moon MJ, Park S, Hwang JI, Kah O, et al. Revisiting the evolution of gonadotropin-releasing hormones and their receptors in vertebrates: secrets hidden in genomes. Gen Comp Endocrinol (2011) 170(1):68-78. doi:10.1016/j.ygcen.2010.10.018
17. Barreiro ML, Tena-Sempere M. Ghrelin and reproduction: a novel signal linking energy status and fertility? Mol Cell Endocrinol (2004) 226(1-2):1-9. doi:10.1016/j.mce.2004.07.015
18. O'Carroll AM, Lolait SJ, Harris LE, Pope GR. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J Endocrinol (2013) 219(1):R13-35. doi:10.1530/JOE-13-0227
19. Pi M, Quarles LD. Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. Endocrinology (2012) 153(5):2062-9. doi:10.1210/en.2011-2117
20. Ferreira AJ, Murça TM, Fraga-Silva RA, Castro CH, Raizada MK, Santos RA. New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens (2012) 2012:147825. doi:10.1155/2012/147825
21. Zurbig P, Jahn H. Use of proteomic methods in the analysis of human body fluids in Alzheimer research. Electrophoresis (2012) 33(24):3617-30. doi:10.1002/elps.201200360
22. Sinha RN. Make dementia a public health priority in India. Indian J Public Health (2011) 55(2):67-9. doi:10.4103/0019-557X.85234
23. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med (2014) 20(4):415-8. doi:10.1038/nm.3466
24. Ferri CP, Sousa R, Albanese E, Ribeiro WS, Honyashiki M. World Alzheimer's Report 2009. In: Prince M, Jackson J, editors. London: Alzheimer's Disease International (2009).
25. Di Domenico F, Sultana R, Barone E, Perluigi M, Cini C, Mancuso C, et al. Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects. J Proteomics (2011) 74(7):1091-103. doi:10.1016/j.jprot.2011.03.033
26. Folch J, Pedrós I, Patraca I, Martínez N, Sureda F, Camins A. Metabolic basis of sporadic Alzheimer's disease. Role of hormones related to energy metabolism. Curr Pharm Des (2013) 19(38):6739-48. doi:10.2174/13816128113199990612
27. Cai H, Cong WN, Ji S, Rothman S, Maudsley S, Martin B. Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res (2012) 9(1):5-17. doi:10.2174/156720512799015064
28. Zabel C, Nguyen HP, Hin SC, Hartl D, Mao L, Klose J. Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders. J Proteomics (2010) 73:2230-8. doi:10.1016/j.jprot.2010.08.008
29. Grela A, Turek A, Piekoszewski W. Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in Alzheimer's disease. Clin Chem Lab Med (2012) 50(8):1297-304. doi:10.1515/cclm-2011-0550
30. Adlard PA, Cummings BJ. Alzheimer's disease-a sum greater than its parts? Neurobiol Aging (2004) 25(6):725-33. doi:10.1016/j.neurobiolaging.2003.12.016
31. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 3(77):77sr1. doi:10.1126/scitranslmed.3002369
32. Moro ML, Giaccone G, Lombardi R, Indaco A, Uggetti A. APP mutations in the Abeta coding region are associated with abundant cerebral deposition of Abeta38. Acta Neuropathol (2012) 124(6):809-21. doi:10.1007/s00401-012-1061-x
33. Chadwick W, Brenneman R, Martin B, Maudsley S. Complex and multidimensional lipid raft alterations in a murine model of Alzheimer's disease. Int J Alzheimers Dis (2010) 2010:604792. doi:10.4061/2010/604792
34. Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J Neurosci Res (2011) 89(6):808-14. doi:10.1002/jnr.22603
35. Watts AS, Loskutova N, Burns JM, Johnson DK. Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults. J Alzheimers Dis (2013) 35(2):253-65. doi:10.3233/JAD-121168
36. Ninomiya T. Diabetes mellitus and dementia. Curr Diab Rep (2014) 14(5):487. doi:10.1007/s11892-014-0487-z
37. Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab (2006) 32(5 Pt 1):403-14. doi:10.1016/S1262-3636(07)70298-7
38. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (2008) 2(6):1101-13. doi:10.1177/193229680800200619
39. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol (2006) 290(3):F625-31.
40. Grunblatt E, Bartl J, Riederer P. The link between iron, metabolic syndrome, and Alzheimer's disease. J Neural Transm (2011) 118(3):371-9. doi:10.1007/s00702-010-0426-3
41. Misiak B, Leszek J, Kiejna A. Metabolic syndrome, mild cognitive impairment and Alzheimer's disease-the emerging role of systemic low-grade inflammation and adiposity. Brain Res Bull (2012) 89(3-4):144-9. doi:10.1016/j.brainresbull.2012.08.003
42. Guix FX, Wahle T, Vennekens K, Snellinx A, Chávez-Gutiérrez L, Ill-Raga G, et al. Modification of g-secretase by nitrosative stress links neuronal ageing to sporadic Alzheimer's disease. EMBO Mol Med (2012) 4:660-73. doi:10.1002/emmm.201200243
43. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J (2011) 75(12):2739-48. doi:10.1253/circj.CJ-11-1184
44. Van Ginneken C, Schäfer KH, Van Dam D, Huygelen V, De Deyn PP. Morphological changes in the enteric nervous system of aging and APP23 transgenic mice. Brain Res (2011) 1378:43-53. doi:10.1016/j.brainres.2011.01.030
45. Semar S, Klotz M, Letiembre M, Van Ginneken C, Braun A, Jost V, et al. Changes of the enteric nervous system in amyloid-ß protein precursor transgenic mice correlate with disease progression. J Alzheimers Dis (2013) 36(1):7-20. doi:10.3233/JAD-120511
46. Fu W, Ruangkittisakul A, MacTavish D, Shi JY, Ballanyi K, Jhamandas JH. Amyloid beta (Abeta) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem (2012) 287(22):18820-30. doi:10.1074/jbc.M111.331181
47. De Vriese C, Delporte C. Influence of ghrelin on food intake and energy homeostasis. Curr Opin Clin Nutr Metab Care (2007) 10(5):615-9. doi:10.1097/MCO.0b013e32829fb37c
48. Theodoropoulou A, Metallinos IC, Psyrogiannis A, Vagenakis GA, Kyriazopoulou V. Ghrelin and leptin secretion in patients with moderate Alzheimer's disease. J Nutr Health Aging (2012) 16(5):472-7. doi:10.1007/s12603-012-0058-4
49. Gahete MD, Rubio A, Córdoba-Chacón J, Gracia-Navarro F, Kineman RD, Avila J, et al. Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis (2010) 22(3):819-28. doi:10.3233/JAD-2010-100873
50. Ma LY, Zhang DM, Tang Y, Lu Y, Zhang Y, Gao Y, et al. Ghrelin-attenuated cognitive dysfunction in streptozotocin-induced diabetic rats. Alzheimer Dis Assoc Disord (2011) 25(4):352-63. doi:10.1097/WAD.0b013e31820ce536
51. Kieffer TJ, Habener JF. The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab (2000) 278(1):E1-14.
52. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest (1998) 101(1):1-9. doi:10.1172/JCI1411
53. Giordano V, Peluso G, Iannuccelli M, Benatti P, Nicolai R, Calvani M. Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia. Neurochem Res (2007) 32(4-5):555-67. doi:10.1007/s11064-006-9125-8
54. Kelleher RJ, Soiza RL. Evidence of endothelial dysfunction in the development of Alzheimer's disease: is Alzheimer's a vascular disorder? Am J Cardiovasc Dis (2013) 3(4):197-226.
55. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature (1996) 380(6570):168-71. doi:10.1038/380168a0
56. Sutton ET, Hellermann GR, Thomas T. Beta-amyloid-induced endothelial necrosis and inhibition of nitric oxide production. Exp Cell Res (1997) 230(2):368-76. doi:10.1006/excr.1996.3440
57. Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab (2013) 33(10):1500-13. doi:10.1038/jcbfm.2013.135
58. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction-Alzheimer's disease of the heart? N Engl J Med (2013) 368(5):455-64. doi:10.1056/NEJMra1106180
59. Coogan AN, Schutová B, Husung S, Furczyk K, Baune BT, Kropp P, et al. The circadian system in Alzheimer's disease: disturbances, mechanisms, and opportunities. Biol Psychiatry (2013) 74(5):333-9. doi:10.1016/j.biopsych.2012.11.021
60. McClung CA. Circadian rhythms and mood regulation: insights from pre-clinical models. Eur Neuropsychopharmacol (2011) 21:S683-93. doi:10.1016/j.euroneuro.2011.07.008
61. Tranah GJ, Blackwell T, Stone KL, Ancoli-Israel S, Paudel ML, Ensrud KE, et al. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol (2011) 70(5):722-32. doi:10.1002/ana.22468
62. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature (2002) 418:935-41. doi:10.1038/nature00965
63. Aliani M, Udenigwe CC, Girgih AT, Pownall TL, Bugera JL, Eskin MN. Aroma and taste perceptions with Alzheimer disease and stroke. Crit Rev Food Sci Nutr (2013) 53(7):760-9. doi:10.1080/10408398.2011.559557
64. Cole LJ, Gavrilescu M, Johnston LA, Gibson SJ, Farrell MJ, Egan GF. The impact of Alzheimer's disease on the functional connectivity between brain regions underlying pain perception. Eur J Pain (2011) 15(6):e1-11. doi:10.1016/j.ejpain.2010.10.010
65. Stover KR, Brown RE. Age-related changes in visual acuity, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav Brain Res (2012) 231(1):75-85. doi:10.1016/j.bbr.2012.02.044
66. Behrman S, Chouliaras L, Ebmeier KP. Considering the senses in the diagnosis and management of dementia. Maturitas (2014) 77(4):305-10. doi:10.1016/j.maturitas.2014.01.003
67. Steinbach S, Hundt W, Vaitl A, Heinrich P, Förster S, Bürger K, et al. Taste in mild cognitive impairment and Alzheimer's disease. J Neurol (2010) 257(2):238-46. doi:10.1007/s00415-009-5300-6
68. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (1999) 67:492-6. doi:10.1136/jnnp.67.4.492
69. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 9:445-54. doi:10.1038/nrneurol.2013.132
70. Antony PM, Diederich NJ, Kruger R, Balling R. The hallmarks of Parkinson's disease. FEBS J (2013) 280:5981-93. doi:10.1111/febs.12335
71. Licker V, Kovari E, Hochstrasser DF, Burkhard PR. Proteomics in human Parkinson's disease research. J Proteomics (2009) 73:10-29. doi:10.1016/j.jprot.2009.07.007
72. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 65:1863-72. doi:10.1212/01.wnl.0000187889.17253.b1
73. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest (2006) 116:1744-54. doi:10.1172/JCI29178
74. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol (2009) 8:464-74. doi:10.1016/S1474-4422(09)70068-7
75. Jellinger KA. Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci (2011) 310:107-11. doi:10.1016/j.jns.2011.04.012
76. Kovari E, Horvath J, Bouras C. Neuropathology of Lewy body disorders. Brain Res Bull (2009) 80:203-10. doi:10.1016/j.brainresbull.2009.06.018
77. Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord (2007) 13(S3):S221-4. doi:10.1016/S1353-8020(08)70005-1
78. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord (2009) 15(S3):S1-5. doi:10.1016/S1353-8020(09)70769-2
79. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 119:689-702. doi:10.1007/s00401-010-0664-3
80. Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M. Parkinson disease: the enteric nervous system spills its guts. Neurology (2011) 77:1761-7. doi:10.1212/WNL.0b013e318236ef60
81. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol (1997) 38(S2):2-7. doi:10.1159/000113469
82. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2003) 24:197-211. doi:10.1016/S0197-4580(02)00065-9
83. Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol (2012) 8:329-39. doi:10.1038/nrneurol.2012.80
84. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECH, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol (2004) 56:173-81. doi:10.1002/ana.20160
85. Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol (1983) 61:101-8. doi:10.1007/BF00697388
86. Petzold GC, Hagiwara A, Murthy VN. Serotonergic modulation of odor input to the mammalian olfactory bulb. Nat Neurosci (2009) 12:784-91. doi:10.1038/nn.2335
87. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol (2003) 60:337-41. doi:10.1001/archneur.60.3.337
88. Cloud LJ, Greene JG. Gastrointestinal features of Parkinson's disease. Curr Neurol Neurosci Rep (2011) 11:379-84. doi:10.1007/s11910-011-0204-0
89. Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology (2009) 73:1752-8. doi:10.1212/WNL.0b013e3181c34af5
90. Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol Dis (2012) 46:559-64. doi:10.1016/j.nbd.2011.10.014
91. Sakakibara R, Kishi M, Ogawa E, Tateno F, Uchiyama T, Yamamoto T, et al. Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinsons Dis (2011) 2011:924605. doi:10.4061/2011/924605
92. Gulyani S, Earley CJ, Camandola S, Maudsley S, Ferré S, Mughal MR, et al. Diminished iron concentrations increase adenosine A(2A) receptor levels in mouse striatum and cultured human neuroblastoma cells. Exp Neurol (2009) 215(2):236-42. doi:10.1016/j.expneurol.2008.10.007
93. Boeve BF, Silber MH, Ferman TJ, Kokmen E, Smith GE. REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology (1998) 51:363-70. doi:10.1212/WNL.51.2.363
94. Muller ML, Bohnen NI. Cholinergic dysfunction in Parkinson's disease. Curr Neurol Neurosci Rep (2013) 13:377. doi:10.1007/s11910-013-0377-9
95. Vendette M, Gagnon JF, Décary A, Massicotte-Marquez J, Postuma RB, Doyon J, et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology (2007) 69:1843-9. doi:10.1212/01.wnl.0000278114.14096.74
96. Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol (2014) 4:805-26. doi:10.1002/cphy.c130026
97. Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis (2012) 46:572-80. doi:10.1016/j.nbd.2011.10.025
98. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol (2007) 17:24-30. doi:10.1111/j.1750-3639.2006.00032.x
99. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain (2008) 131:642-50. doi:10.1093/brain/awm302
100. Barrio JR, Huang SC, Melega WP, Yu DC, Hoffman JM, Schneider JS, et al. 6-[18F]fluoro-l-dopa probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res (1990) 27:487-93. doi:10.1002/jnr.490270408
101. Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH. MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord (2009) 24:1650-5. doi:10.1002/mds.22649
102. Benarroch EE. The arterial baroreflex: functional organization and involvement in neurologic disease. Neurology (2008) 71:1733-8. doi:10.1212/01.wnl.0000335246.93495.92
103. Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord (2011) 17:625-8. doi:10.1016/j.parkreldis.2011.05.020
104. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol (2004) 61:661-6. doi:10.1001/archneur.61.5.661
105. Xu Q, Park Y, Huang X, Hollenbeck A, Blair A. Diabetes and risk of Parkinson's disease. Diabetes Care (2011) 34:910-5. doi:10.2337/dc10-1922
106. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain (2013) 136:374-84. doi:10.1093/brain/aws009
107. Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol Med (2013) 19:176-86. doi:10.1016/j.molmed.2013.01.002
108. Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol (1991) 36:343-62. doi:10.1016/0301-0082(91)90015-S
109. Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano P. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation. J Neurochem (2008) 106:560-77. doi:10.1111/j.1471-4159.2008.05406.x
110. Russo I, Barlati S, Bosetti F. Effects of neuroinflammation on the regenerative capacity of brain stem cells. J Neurochem (2011) 116(6):947-56. doi:10.1111/j.1471-4159.2010.07168.x
111. Pradhan S, Andreasson K. Commentary: progressive inflammation as a contributing factor to early development of Parkinson's disease. Exp Neurol (2013) 241:148-55. doi:10.1016/j.expneurol.2012.12.008
112. Russo I, Bubacco L, Greggio E. LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? J Neuroinflammation (2014) 11:52. doi:10.1186/1742-2094-11-52
113. Lu M, Hu G. Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies. Clin Exp Pharmacol Physiol (2012) 39(6):577-85. doi:10.1111/j.1440-1681.2011.05650.x
114. Martin B, Golden E, Keselman A, Stone M, Mattson MP, Egan JM, et al. Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. Histol Histopathol (2008) 23(2):237-50.
115. Collaborative Group HD. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell (1993) 72(6):971-83. doi:10.1016/0092-8674(93)90585-E
116. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 293(5529):493-8. doi:10.1126/science.1059581
117. Hoffner G, Kahlem P, Djian P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J Cell Sci (2002) 115(5):941-8.
118. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron (1995) 14(5):1075-81. doi:10.1016/0896-6273(95)90346-1
119. Velier J, Kim M, Schwarz C, Kim TW, Sapp E, Chase K, et al. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp Neurol (1998) 152(1):34-40. doi:10.1006/exnr.1998.6832
120. Morton AJ. Circadian and sleep disorder in Huntington's disease. Exp Neurol (2013) 243:34-44. doi:10.1016/j.expneurol.2012.10.014
121. Aziz NA, Pijl H, Frölich M, Snel M, Streefland TC, Roelfsema F, et al. Systemic energy homeostasis in Huntington's disease patients. J Neurol Neurosurg Psychiatry (2010) 81(11):1233-7. doi:10.1136/jnnp.2009.191833
122. Cong WN, Cai H, Wang R, Daimon CM, Maudsley S, Raber K, et al. Altered hypothalamic protein expression in a rat model of Huntington's disease. PLoS One (2012) 7(10):e47240. doi:10.1371/journal.pone.0047240
123. Aziz NA, Pijl H, Frölich M, Schröder-van der Elst JP, van der Bent C, Roelfsema F, et al. Delayed onset of the diurnal melatonin rise in patients with Huntington's disease. J Neurol (2009) 256(12):1961-5. doi:10.1007/s00415-009-5196-1
124. Farrer LA. Diabetes mellitus in Huntington disease. Clin Genet (1985) 27:62-7. doi:10.1111/j.1399-0004.1985.tb00185.x
125. Dorsey ER, Beck CA, Brenna JT, Shoulson I. Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol (2010) 4(1):17-23. doi:10.1016/j.jacl.2009.11.003
126. Hunt MJ, Morton AJ. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res (2005) 166:220-9. doi:10.1007/s00221-005-2357-z
127. Lalic NM, Maric J, Svetel M, Jotic A, Stefanova E, Lalic K, et al. Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol (2008) 65(4):476-80. doi:10.1001/archneur.65.4.476
128. Geroldi C, Frisoni GB, Paolisso G, Bandinelli S, Lamponi M, Abbatecola AM, et al. Insulin resistance in cognitive impairment: the InCHIANTI study. Arch Neurol (2005) 62(7):1067-72. doi:10.1001/archneur.62.7.1067
129. Hult S, Soylu R, Björklund T, Belgardt BF, Mauer J, Brüning JC, et al. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab (2011) 13(4):428-39. doi:10.1016/j.cmet.2011.02.013
130. van der Burg JM, Winqvist A, Aziz NA, Maat-Schieman ML, Roos RA, Bates GP, et al. Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice. Neurobiol Dis (2011) 44(1):1-8. doi:10.1016/j.nbd.2011.05.006
131. Kudo T, Schroeder A, Loh DH, Kuljis D, Jordan MC, Roos KP, et al. Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease. Exp Neurol (2011) 228(1):80-90. doi:10.1016/j.expneurol.2010.12.011
132. Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci (2005) 25(1):157-63. doi:10.1523/JNEUROSCI.3842-04.2005
133. Pallier PN, Maywood ES, Zheng Z, Chesham JE, Inyushkin AN, Dyball R, et al. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J Neurosci (2007) 27(29):7869-78. doi:10.1523/JNEUROSCI.0649-07.2007
134. Pallier PN, Morton AJ. Management of sleep/wake cycles improves cognitive function in a transgenic mouse model of Huntington's disease. Brain Res (2009) 1279:90-8. doi:10.1016/j.brainres.2009.03.072
135. Maywood ES, Fraenkel E, McAllister CJ, Wood N, Reddy AB, Hastings MH, et al. Disruption of peripheral circadian timekeeping in a mouse model of Huntington's disease and its restoration by temporally scheduled feeding. J Neurosci (2010) 30(30):10199-204. doi:10.1523/JNEUROSCI.1694-10.2010
136. Bates GP, Harper PS, Jones L, editors. Huntington's Disease. Third ed. Oxford: Oxford University Press (2002).
137. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry (2004) 65(Suppl 16):27-32.
138. Sephton S, Spiegel D. Circadian disruption in cancer: a neuroendocrine immune pathway from stress to disease? Brain Behav Immun (2003) 17:321-8. doi:10.1016/S0889-1591(03)00078-3
139. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med (2004) 7:846-50.
140. Eismann EA, Lush E, Sephton SE. Circadian effects in cancer relevant psychoneuroendocrine and immune pathways. Psychoneuroendocrinology (2010) 35:963-76. doi:10.1016/j.psyneuen.2009.12.011
141. Kiriazis H, Jennings NL, Davern P, Lambert G, Su Y, Pang T, et al. Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease. J Physiol (2012) 590(Pt 22):5845-60. doi:10.1113/jphysiol.2012.238113
142. Buonincontri G, Wood NI, Puttick SG, Ward AO, Carpenter TA, Sawiak SJ, et al. Right ventricular dysfunction in the R6/2 transgenic mouse model of Huntington's disease is unmasked by dobutamine. J Huntingtons Dis (2014) 3(1):25-32. doi:10.3233/JHD-130083
143. Schroeder AM, Loh DH, Jordan MC, Roos KP, Colwell CS. Baroreceptor reflex dysfunction in the BACHD mouse model of Huntington's disease. PLoS Curr (2011) 3:RRN1266. doi:10.1371/currents.RRN1266
144. van der Burg JMM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol (2009) 8:765-74. doi:10.1016/S1474-4422(09)70178-4
145. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation (2008) 117:2743-51. doi:10.1161/CIRCULATIONAHA.107.750232
146. Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med (2008) 205(8):1869-77. doi:10.1084/jem.20080178
147. Kwan W, Träger U, Davalos D, Chou A, Bouchard J, Andre R, et al. Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest (2012) 122(12):4737-47. doi:10.1172/JCI64484
148. Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, et al. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr (2011) 3:RRN1231. doi:10.1371/currents.RRN1231
149. Hsiao HY, Chiu FL, Chen CM, Wu YR, Chen HM, Chen YC, et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. Hum Mol Genet (2014) 23(16):4328-44. doi:10.1093/hmg/ddu151
150. O'Donnell BF, Blekher TM, Weaver M, White KM, Marshall J, Beristain X, et al. Visual perception in prediagnostic and early stage Huntington's disease. J Int Neuropsychol Soc (2008) 14(3):446-53. doi:10.1017/S1355617708080405
151. Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SM, Hyare H, et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp (2013) 34(3):519-29. doi:10.1002/hbm.21449
152. Mitchell IJ, Heims H, Neville EA, Rickards H. Huntington's disease patients show impaired perception of disgust in the gustatory and olfactory modalities. J Neuropsychiatry Clin Neurosci (2005) 17(1):119-21.
153. Gardiner J, Barton D, Vanslambrouck JM, Braet F, Hall D, Marc J, et al. Defects in tongue papillae and taste sensation indicate a problem with neurotrophic support in various neurological diseases. Neuroscientist (2008) 14(3):240-50. doi:10.1177/1073858407312382
154. Zhou J, Livak MF, Bernier M, Muller DC, Carlson OD, Elahi D, et al. Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab (2007) 293(2):E538-47. doi:10.1152/ajpendo.00070.2007
155. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrionol (1993) 138:159-66. doi:10.1677/joe.0.1380159
156. Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes (1993) 42:1678-82. doi:10.2337/diabetes.42.11.1678
157. Chapter MC, White CM, DeRidder A, Chadwick W, Martin B, Maudsley S. Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol Ther (2010) 125:39-54. doi:10.1016/j.pharmthera.2009.07.006
158. Martin B, Lopez de Maturana R, Brenneman R, Walent T, Mattson MP, Maudsley S. Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular Med (2005) 7(1-2):3-36. doi:10.1385/NMM:7:1-2:003
159. Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC, Olefsky JM. Beta-arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc Natl Acad Sci USA (2008) 105(18):6614-9. doi:10.1073/pnas.0710402105
160. Ladenheim EE. Gastrointestinal regulatory peptides and central nervous system mechanisms of weight control. Curr Opin Endocrinol Diabetes Obes (2012) 19(1):13-8. doi:10.1097/MED.0b013e32834ea723
161. Cai H, Maudsley S, Martin B. What is the role of metabolic hormones in taste buds of the tongue. Front Horm Res (2014) 42:134-46. doi:10.1159/000358322
162. Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther (2004) 309(2):469-75. doi:10.1124/jpet.103.063222
163. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol (2014) 221(1):T1-16. doi:10.1530/JOE-13-0414
164. Kim BJ, Zhou J, Martin B, Carlson OD, Maudsley S, Greig NH, et al. Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. J Pharmacol Exp Ther (2010) 334(3):682-92. doi:10.1124/jpet.110.166470
165. Phillips LK, Prins JB. Update on incretin hormones. Ann N Y Acad Sci (2011) 1243:E55-74. doi:10.1111/j.1749-6632.2012.06491.x
166. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med (2007) 48(5):736-43. doi:10.2967/jnumed.106.038679
167. Hölscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs (2012) 26(10):871-82. doi:10.2165/11635890-000000000-00000
168. Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes (2009) 58(2):318-28. doi:10.2337/db08-0799
169. Ahrén B. GLP-1 and extra-islet effects. Horm Metab Res (2004) 36(11-12):842-5. doi:10.1055/s-2004-826173
170. Cai H, Daimon CM, Cong WN, Wang R, Chirdon P, de Cabo R, et al. Longitudinal analysis of calorie restriction on rat taste bud morphology and expression of sweet taste modulators. J Gerontol A Biol Sci Med Sci (2014) 69(5):532-44. doi:10.1093/gerona/glt129
171. Avogaro A, Vigili de Kreutzenberg S, Fadini GP. Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. Curr Diab Rep (2014) 14(5):483. doi:10.1007/s11892-014-0483-3
172. Gil-Lozano M, Romaní-Pérez M, Outeiriño-Iglesias V, Vigo E, Brubaker PL, González-Matías LC, et al. Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance. Am J Physiol Endocrinol Metab (2013) 304(10):E1105-17. doi:10.1152/ajpendo.00529.2012
173. Brunner JI, Gotter AL, Millstein J, Garson S, Binns J, Fox SV, et al. Pharmacological validation of candidate causal sleep genes identified in an N2 cross. J Neurogenet (2011) 25(4):167-81. doi:10.3109/01677063.2011.628426
174. Martin B, Chadwick W, Cong WN, Pantaleo N, Daimon CM, Golden EJ, et al. Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy. J Biol Chem (2012) 287(38):31766-82. doi:10.1074/jbc.M112.387316
175. Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, et al. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim Biophys Acta (2013) 1832(4):527-41. doi:10.1016/j.bbadis.2013.01.008
176. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest (2013) 123(6):2730-6. doi:10.1172/JCI68295
177. Chen S, An FM, Yin L, Liu AR, Yin DK, Yao WB, et al. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience (2014) 256:137-46. doi:10.1016/j.neuroscience.2013.10.038
178. Hölscher C. The incretin hormones glucagon like peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimers Dement (2014) 10(1S):S47-54. doi:10.1016/j.jalz.2013.12.009
179. Maudsley S, Davidson L, Pawson AJ, Chan R, López de Maturana R, et al. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res (2004) 64(20):7533-44. doi:10.1158/0008-5472.CAN-04-1360
180. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 368(9548):1696-705. doi:10.1016/S0140-6736(06)69705-5
181. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem (2000) 43:1664-9. doi:10.1021/jm9909645
182. Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, et al. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem (2005) 16:377-82. doi:10.1021/bc049735+
183. Siegel EG, Scharf G, Gallwitz B, Mentlein R, Morys-Wortmann C, Fölsch UR, et al. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Eur J Clin Invest (1999) 29:610-4. doi:10.1046/j.1365-2362.1999.00440.x
184. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept (2004) 117(2):77-88. doi:10.1016/j.regpep.2003.10.028
185. Moon HS, Kim MK, Son MH. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes. Arch Pharm Res (2011) 34(7):1041-3. doi:10.1007/s12272-011-0721-z
186. Morris LC, Days EL, Turney M, Mi D, Lindsley CW, Weaver CD, et al. A duplexed high-throughput screen to identify allosteric modulators of the Glucagon-Like Peptide 1 and Glucagon receptors. J Biomol Screen (2014) 19(6):847-58. doi:10.1177/1087057114520971
187. Zhang YJ, Shen LL, Cheon HG, Xu YN, Jeong JH. Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists. Arch Pharm Res (2014) 37(5):588-99. doi:10.1007/s12272-013-0253-9
188. Koole C, Wootten D, Simms J. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol (2010) 78:456-65. doi:10.1124/mol.110.065664
189. Chen D, Liao J, Li N. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci USA (2007) 104:943-8. doi:10.1073/pnas.0610173104
190. Sloop KW, Willard FS, Brenner MB. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes (2010) 59:3099-107. doi:10.2337/db10-0689
191. Knudsen LB, Kiel D, Teng M. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci USA (2007) 104:937-42. doi:10.1073/pnas.0605701104
192. Willard FS, Wootten D, Showalter AD. Small molecule allosteric modulation of the glucagon-like peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. Mol Pharmacol (2012) 82:1066-73. doi:10.1124/mol.112.080432
193. Wootten D, Savage EE, Valant C, May LT. Allosteric modulation of endogenous metabolites as an avenue for drug discovery. Mol Pharmacol (2012) 82:281-90. doi:10.1124/mol.112.079319
194. Mapelli C, Natarajan SI, Meyer JP. Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. J Med Chem (2009) 52:7788-99. doi:10.1021/jm900752a
195. Koole C, Savage EE, Christopoulos A, Miller LJ, Sexton PM, Wootten D. Minireview: signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery. Mol Endocrinol (2013) 27(8):1234-44. doi:10.1210/me.2013-1116
196. Montrose-Rafizadeh C, Avdonin P, Garant MJ. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology (1999) 140:1132-40. doi:10.1210/endo.140.3.6550
197. Quoyer J, Longuet C, Broca C. GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a ß-arrestin 1-mediated ERK1/2 activation in pancreatic ß-cells. J Biol Chem (2010) 285:1989-2002. doi:10.1074/jbc.M109.067207
198. Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, et al. The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem (2000) 275(13):9572-80. doi:10.1074/jbc.275.13.9572
199. Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic ß-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes (2003) 52:124-32. doi:10.2337/diabetes.52.1.124
200. Martin B, Chen H, Daimon CM, Chadwick W, Siddiqui S, Maudsley S. Plurigon: three dimensional visualization and classification of high-dimensionality data. Front Physiol (2013) 4:190. doi:10.3389/fphys.2013.00190
201. Wootten D, Savage EE, Willard FS, Bueno AB, Sloop KW, Christopoulos A, et al. Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. Mol Pharmacol (2013) 83(4):822-34. doi:10.1124/mol.112.084525
202. Coopman K, Huang Y, Johnston N, Bradley SJ, Wilkinson GF, Willars GB. Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor. J Pharmacol Exp Ther (2010) 334:795-808. doi:10.1124/jpet.110.166009
203. Wootten D, Simms J, Koole C. Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. J Pharmacol Exp Ther (2011) 336:540-50. doi:10.1124/jpet.110.176362
204. Harikumar KG, Wootten D, Pinon DI, Koole C, Ball AM, Furness SG, et al. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proc Natl Acad Sci USA (2012) 109(45):18607-12. doi:10.1073/pnas.1205227109
205. de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol (2014) 88(4):548-59. doi:10.1016/j.bcp.2013.12.012
206. Amadoro G, Corsetti V, Florenzano F, Atlante A, Bobba A, Nicolin V, et al. Morphological and bioenergetic demands underlying the mitophagy in post-mitotic neurons: the pink-parkin pathway. Front Aging Neurosci (2014) 6:18. doi:10.3389/fnagi.2014.00018
207. Morais VA, Haddad D, Craessaerts K, De Bock PJ, Swerts J, Vilain S, et al. PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling. Science (2014) 344(6180):203-7. doi:10.1126/science.1249161
208. Bassil F, Fernagut PO, Bezard E, Meissner WG. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol (2014) 118C:1-18. doi:10.1016/j.pneurobio.2014.02.005
209. Umegaki H. Neurodegeneration in diabetes mellitus. Adv Exp Med Biol (2012) 724:258-65. doi:10.1007/978-1-4614-0653-2_19